GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beyond Air XAIR · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.29

+6.02%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beyond Air

From its filings with the US Securities and Exchange Commission

SEC filings

Beyond Air is based in Garden City, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker XAIR. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 March 2026, it reported revenue of $7.7m and a net loss of $33.2m. At that date it held total assets of $35.4m and shareholders' equity of $6.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
7 May 2019
Employees
23
Head office
900 STEWART AVENUE, GARDEN CITY, NY, 11530
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Steven LisiChief Executive Officer and Chairman of the Board, since 2017$821,140
  • Mr. Douglas LarsonChief Financial Officer$405,276
  • Mr. Michael GaulChief Operating Officer$464,872
  • Mr. Robert CareyIndependent Director$90,918
  • Dr. William ForbesIndependent Director$17,025
  • Mr. Robert GoodmanIndependent Director
  • Ms. Yoori LeeIndependent Director$17,025
  • Mr. Erick LuceraIndependent Director$17,025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
9
Environment
10
Social
13
Governance
6
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is clinical-stage with focus on nitric oxide generator and delivery system
  • Headquartered in Garden City, New York with 23 employees
  • Products include Beyond Air-PH, Beyond Air-BRO, and Beyond Air-NTM

Weaknesses

  • Company has only 23 employees
  • IPO occurred in 2019 with no mention of recent funding
  • Company is clinical-stage with no commercial products yet

Opportunities

  • Potential market for nitric oxide delivery systems in PPHN, BRO, and NTM treatments
  • Focus on persistent pulmonary hypertension of the newborn (PPHN) and bronchiolitis (BRO)
  • High concentration nitric oxide delivery system could address unmet medical needs

Threats

  • Clinical-stage company faces development and regulatory risks
  • Limited employee count may hinder growth and operations
  • No commercial products indicate dependency on successful clinical trials

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.